Shares of Incyte (INCY) have risen 12.7% in the past six months against the industry's decline of 0.5%. The stock has also outperformed the sector and the S&P 500 during this time frame. The outperformance can be attributed to positive data readouts and new drug approvals. Lead drug Jakafi (ruxolitinib) also maintains momentum. INCY Outperforms Industry, Sector and S&P 500 Image Source: Zacks Investment Research INCY's Lead Drug Jakafi Maintains Momentum Incyte's lead drug, Jakafi, is a JAK1/JAK2 inhibitor ...